Ocuphire Pharma (OCUP)
(Delayed Data from NSDQ)
$1.32 USD
+0.03 (2.33%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $1.33 +0.01 (0.76%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth C Momentum C VGM
Brokerage Reports
0 items in cart
Ocuphire Pharma, Inc. [OCUP]
Reports for Purchase
Showing records 1 - 20 ( 24 total )
Company: Ocuphire Pharma, Inc.
Industry: Medical - Biomedical and Genetics
Partnered Phentolamine Approaches 2025 Data As APX3330 Path Being Defined; Reduced PT to $18 With Model Adjustment
Provider: H.C. Wainwright & Co., Inc.
Analyst: CAUFIELD M
Company: Ocuphire Pharma, Inc.
Industry: Medical - Biomedical and Genetics
Boots on the Ground at CTS 2024-New Innovations in the Retina
Provider: H.C. Wainwright & Co., Inc.
Analyst: CAUFIELD M
Company: Ocuphire Pharma, Inc.
Industry: Medical - Biomedical and Genetics
APX3330 Anticipated SPA Agreement Forthcoming and Partnered Ryzumvi Launch; Reit. Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CAUFIELD M
Company: Ocuphire Pharma, Inc.
Industry: Medical - Biomedical and Genetics
Focusing Sights on Oral APX3330 Phase 3 Advancement in NPDR; Reit. Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CAUFIELD M
Company: Ocuphire Pharma, Inc.
Industry: Medical - Biomedical and Genetics
Oral APX3330 Advancement in DR, With Partnered Nyxol Approval in RM; Reit. Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CAUFIELD M
Company: Ocuphire Pharma, Inc.
Industry: Medical - Biomedical and Genetics
Boots on the Ground at AAO?23-KOL Perspectives and Considerations on Therapeutic Ophthalmic Innovations
Provider: H.C. Wainwright & Co., Inc.
Analyst: CAUFIELD M
Company: Ocuphire Pharma, Inc.
Industry: Medical - Biomedical and Genetics
FDA Approval of Ryzumvi in RM Sets Stage For Partnered Nyxol Platform; Reit Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CAUFIELD M
Company: Ocuphire Pharma, Inc.
Industry: Medical - Biomedical and Genetics
2023 As Year of Platform Catalysts Across Both APX3330 and Nyxol; Reit. Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CAUFIELD M
Company: Ocuphire Pharma, Inc.
Industry: Medical - Biomedical and Genetics
Nyxol PDUFA Approaches While Determining APX3330 Path Forward; Reit Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CAUFIELD M
Company: Ocuphire Pharma, Inc.
Industry: Medical - Biomedical and Genetics
Broad Nyxol Refractive Platform Advancement to Define 2023; Reit Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CAUFIELD M
Company: Ocuphire Pharma, Inc.
Industry: Medical - Biomedical and Genetics
Focusing Broadly on Nyxol, With APX3330 Further Pipeline Upside; Reit Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CAUFIELD M
Company: Ocuphire Pharma, Inc.
Industry: Medical - Biomedical and Genetics
ZETA-1 Primary Endpoint Miss to Determine APX3330 Path; Adjustments With Announced Partnership; PT Down to $20
Provider: H.C. Wainwright & Co., Inc.
Analyst: CAUFIELD M
Company: Ocuphire Pharma, Inc.
Industry: Medical - Biomedical and Genetics
Nyxol Global License Agreement Paves Refractive Path Forward
Provider: H.C. Wainwright & Co., Inc.
Analyst: CAUFIELD M
Company: Ocuphire Pharma, Inc.
Industry: Medical - Biomedical and Genetics
Platform Firing on All Cylinders-ZETA-1 Data and Nyxol NDA in Near Term; Reit. Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CAUFIELD M
Company: Ocuphire Pharma, Inc.
Industry: Medical - Biomedical and Genetics
APX3330-KOL Perspectives on Oral Therapy in DR/DME, Top-Line Expected 4Q22
Provider: H.C. Wainwright & Co., Inc.
Analyst: CAUFIELD M
Company: Ocuphire Pharma, Inc.
Industry: Medical - Biomedical and Genetics
Planned Nyxol NDA in RM, Broader Pipeline Catalysts to Define 2022; Reit. Buy and $26 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: CAUFIELD M
Company: Ocuphire Pharma, Inc.
Industry: Medical - Biomedical and Genetics
Phase 3 LYNX-1 Trial Delivers Diversification for Refractive Platform
Provider: H.C. Wainwright & Co., Inc.
Analyst: CAUFIELD M
Company: Ocuphire Pharma, Inc.
Industry: Medical - Biomedical and Genetics
Nyxol Catalysts Set Stage for 2022; APX3330 Top-Line Expected 2H22
Provider: H.C. Wainwright & Co., Inc.
Analyst: CAUFIELD M
Company: Ocuphire Pharma, Inc.
Industry: Medical - Biomedical and Genetics
MIRA Program Success Paves Way to Anticipated Late 2022 NDA Submission in RM
Provider: H.C. Wainwright & Co., Inc.
Analyst: CAUFIELD M
Company: Ocuphire Pharma, Inc.
Industry: Medical - Biomedical and Genetics
Phase 3 MIRA-3 Clarity in RM Asserts Nyxol Impact for Pupil Modulation
Provider: H.C. Wainwright & Co., Inc.
Analyst: CAUFIELD M